IL268417B2 - Methods for cell-type specific profiling to identify drug targets - Google Patents

Methods for cell-type specific profiling to identify drug targets

Info

Publication number
IL268417B2
IL268417B2 IL268417A IL26841719A IL268417B2 IL 268417 B2 IL268417 B2 IL 268417B2 IL 268417 A IL268417 A IL 268417A IL 26841719 A IL26841719 A IL 26841719A IL 268417 B2 IL268417 B2 IL 268417B2
Authority
IL
Israel
Prior art keywords
tissue sample
nuclei
nucleus
affinity labels
isolating
Prior art date
Application number
IL268417A
Other languages
English (en)
Hebrew (he)
Other versions
IL268417B1 (en
IL268417A (en
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Publication of IL268417A publication Critical patent/IL268417A/en
Publication of IL268417B1 publication Critical patent/IL268417B1/en
Publication of IL268417B2 publication Critical patent/IL268417B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Data Mining & Analysis (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
IL268417A 2017-02-10 2018-02-09 Methods for cell-type specific profiling to identify drug targets IL268417B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457420P 2017-02-10 2017-02-10
US201762558396P 2017-09-14 2017-09-14
PCT/US2018/017556 WO2018148501A1 (en) 2017-02-10 2018-02-09 Methods for cell-type specific profiling to identify drug targets

Publications (3)

Publication Number Publication Date
IL268417A IL268417A (en) 2019-09-26
IL268417B1 IL268417B1 (en) 2025-01-01
IL268417B2 true IL268417B2 (en) 2025-05-01

Family

ID=63107837

Family Applications (1)

Application Number Title Priority Date Filing Date
IL268417A IL268417B2 (en) 2017-02-10 2018-02-09 Methods for cell-type specific profiling to identify drug targets

Country Status (11)

Country Link
US (1) US12577609B2 (https=)
EP (2) EP3580338B1 (https=)
JP (3) JP7229538B2 (https=)
CN (2) CN110582578B (https=)
AU (2) AU2018219308B2 (https=)
CA (1) CA3052290A1 (https=)
ES (1) ES2992087T3 (https=)
IL (1) IL268417B2 (https=)
MX (2) MX2019009612A (https=)
SG (1) SG11201907162TA (https=)
WO (1) WO2018148501A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019152543A1 (en) * 2018-01-31 2019-08-08 Dovetail Genomics, Llc Sample prep for dna linkage recovery
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
JP2022544496A (ja) * 2019-08-12 2022-10-19 ミッション バイオ インコーポレイテッド 同一のシングルセルにおける、タンパク質発現、一塩基変化、及びコピー数多型のマルチオミクス同時検出のための方法、システム、及び装置
CN114375328B (zh) * 2019-09-06 2024-12-27 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN110699362B (zh) * 2019-11-15 2023-03-24 兰州理工大学 Afp5基因及其应用
CN111312330A (zh) * 2020-02-13 2020-06-19 兰州理工大学 一种基于蛋白质节点特性的关键蛋白质识别方法及系统
EP4146831A4 (en) * 2020-05-06 2024-05-15 Dignity Health SYSTEMS AND METHODS FOR TREATING LEVODOPA-INDUCED DYSKINESIA, IMPROVING MOTOR BENEFITS AND DELAYING DISEASE PROGRESSION
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN112538480B (zh) * 2020-12-24 2022-09-27 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 精子鞭毛多发形态异常疾病动物模型的构建方法和应用
CN112522425B (zh) * 2020-12-25 2023-11-28 武汉睿健医药科技有限公司 Dpc细胞鉴定分类用标记物基因、筛选方法及应用
CN112481273B (zh) * 2020-12-29 2023-11-24 南通大学附属医院 结直肠癌抑癌基因及其启动子区高dna甲基化的验证方法
CN113186281B (zh) * 2021-04-02 2023-02-28 广州医科大学附属第五医院 作为肝细胞癌标志物的inava
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US11946928B2 (en) * 2021-05-20 2024-04-02 Trustees Of Boston University Methods and compositions relating to airway dysfunction
US20240254514A1 (en) * 2021-05-21 2024-08-01 Allen Institute Artificial expression constructs for modulating gene expression in neurons within the thalamus
CN113495167B (zh) * 2021-06-24 2024-05-03 迈克医疗电子有限公司 血细胞分析仪的试剂加载方法及装置
CN113558011B (zh) * 2021-07-23 2022-05-10 深圳市中医院 基于γ-分泌酶激活蛋白基因的干燥综合征动物模型的建立方法
CN113652486B (zh) * 2021-09-13 2023-02-03 新疆医科大学第四附属医院 结直肠癌治疗预后生物标志物及其应用
CN113893892B (zh) * 2021-11-10 2023-02-10 大连海事大学 一种基于微流控芯片的纳米孔及其制备方法
CN114276993A (zh) * 2021-11-11 2022-04-05 上海昆盟生物科技有限公司 一种用于分离大鼠下丘脑弓状核神经元的方法
CN116297884A (zh) * 2021-12-01 2023-06-23 中国科学院大连化学物理研究所 一种基于mrm技术对工程菌株mva途径多靶标蛋白质的检测方法
CN114457075B (zh) * 2021-12-15 2023-05-02 徐州市中心医院 一种敲低PXYLP1基因表达的shRNA、慢病毒载体及其构建方法和应用
US20230191222A1 (en) * 2021-12-21 2023-06-22 Shuhari Group, LLC Impact And Movement Sensing To Measure Performance
CN114807124B (zh) * 2022-04-01 2023-09-12 上海信诺佰世医学检验有限公司 一种检测alk融合基因的引物和探针组合物、试剂盒及方法
CN114751990B (zh) * 2022-04-01 2023-10-20 中国科学技术大学 酰胺高丝氨酸内酯受体-增强绿色荧光融合蛋白及其制备方法与应用
EP4518871A1 (en) * 2022-05-05 2025-03-12 Alnylam Pharmaceuticals, Inc. Actin-binding lim protein 3 (ablim3) irna agent compositions and methods of use thereof
CN115096978B (zh) * 2022-05-26 2025-06-27 核工业理化工程研究院 一种稳定同位素丰度的质谱测定方法
CN114875033A (zh) * 2022-06-29 2022-08-09 福建省医学科学研究院 sgRNA、CRISPR/Cas试剂及其应用
CN115161260B (zh) * 2022-07-01 2023-07-14 中国人民解放军空军军医大学 Mal-PEG6-NHS-ester在外泌体示踪修饰中的应用和外泌体修饰的方法
CN115083522B (zh) * 2022-08-18 2022-10-28 天津诺禾致源生物信息科技有限公司 细胞类型的预测方法、装置及服务器
CN115508176A (zh) * 2022-09-30 2022-12-23 昆明理工大学 一种基于非标记的三七总皂苷治疗神经退行性疾病的靶点筛选方法
CN116004773B (zh) * 2022-09-30 2025-04-08 华南农业大学 一种线性置换等温扩增方法及其应用
CN116144655A (zh) * 2022-10-12 2023-05-23 中国农业科学院兰州兽医研究所 一种瞬时靶向干扰HS3ST5基因表达的siRNA及其应用
CN115850516B (zh) * 2022-11-16 2024-06-11 西北农林科技大学 鱼类蛋白自组装纳米抗原及其制备的疫苗与应用
CN115927596A (zh) * 2022-12-02 2023-04-07 中国科学技术大学 一种用于诊断小鼠小脑衰老的生物标记物及其应用
CN121889502A (zh) * 2023-04-06 2026-04-17 科洛索生物科学有限公司 长毛猛犸象特异性基因变体及包含其的组合物
CN121693563A (zh) * 2023-04-13 2026-03-17 5端生物科技股份有限公司 上调逆转录和降低rna测序中序列偏好性的组合物和方法
CN117590001A (zh) * 2023-11-22 2024-02-23 厦门大学 外泌体tmem176b在制备诊断肿瘤的药物中的用途
CN117925846B (zh) * 2024-03-25 2024-06-11 包头市中心医院 一种用于胃癌预后评价的生物标记物及其应用
CN118726571B (zh) * 2024-07-23 2025-02-14 南京市第一医院 主动脉夹层分子标志物及其应用
CN119804865B (zh) * 2024-12-31 2025-10-24 郑州大学 细胞外囊泡蛋白质作为诊断腹主动脉瘤的生物标志物及应用
CN119614700B (zh) * 2025-02-13 2025-06-10 南昌大学第一附属医院 MybpC1基因/蛋白在制备骨关节炎药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110071049A1 (en) * 2008-03-12 2011-03-24 Nathaniel Heintz Methods and compositions for translational profiling and molecular phenotyping
US8299233B2 (en) * 2008-01-04 2012-10-30 Centre National De La Recherche Scientifique Molecular in vitro diagnosis of breast cancer
WO2016092070A1 (en) * 2014-12-11 2016-06-16 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Genome architecture mapping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936582B1 (en) * 1997-09-09 2005-08-30 Curis, Inc. Synergistic effects of OP/BMP morphogens and GDNF/NGF neurotrophic factors
ES2277567B1 (es) * 2005-12-30 2008-06-01 Universidad Del Pais Vasco Compuestos con propiedades neuroprotectoras.
WO2012105854A2 (en) * 2011-01-31 2012-08-09 Curonz Holdings Company Limited Compositions for administration to the eye
US9758809B2 (en) * 2013-03-06 2017-09-12 Emory University RNA splicing alterations and U1 small nuclear ribonucleoproteins in neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299233B2 (en) * 2008-01-04 2012-10-30 Centre National De La Recherche Scientifique Molecular in vitro diagnosis of breast cancer
US20110071049A1 (en) * 2008-03-12 2011-03-24 Nathaniel Heintz Methods and compositions for translational profiling and molecular phenotyping
WO2016092070A1 (en) * 2014-12-11 2016-06-16 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Genome architecture mapping

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PREISSL ET AL, " DECIPHERING THE EPIGENETIC CODE OF CARDIAC MYOCYTE TRANSCRIPTION", 14 August 2015 (2015-08-14) *
RISCA ET AL, " UNRAVELING THE 3D GENOME: GENOMICS TOOLS FOR MULTI-SCALE EXPLORATION", 1 July 2015 (2015-07-01) *

Also Published As

Publication number Publication date
JP2023058610A (ja) 2023-04-25
JP7229538B2 (ja) 2023-03-01
EP3580338A1 (en) 2019-12-18
EP4461818A2 (en) 2024-11-13
MX2024000814A (es) 2024-02-06
JP2025032204A (ja) 2025-03-11
EP3580338C0 (en) 2024-09-11
IL268417B1 (en) 2025-01-01
ES2992087T3 (es) 2024-12-09
MX2019009612A (es) 2019-11-12
IL268417A (en) 2019-09-26
US20210095334A1 (en) 2021-04-01
CN110582578B (zh) 2024-02-02
CN117965689A (zh) 2024-05-03
CN110582578A (zh) 2019-12-17
EP3580338A4 (en) 2021-05-26
EP3580338B1 (en) 2024-09-11
WO2018148501A1 (en) 2018-08-16
US12577609B2 (en) 2026-03-17
AU2018219308A1 (en) 2019-08-22
JP7604014B2 (ja) 2024-12-23
EP4461818A3 (en) 2025-02-12
SG11201907162TA (en) 2019-09-27
AU2024259851A1 (en) 2024-12-12
CA3052290A1 (en) 2018-08-16
AU2018219308B2 (en) 2024-08-08
JP2020508652A (ja) 2020-03-26

Similar Documents

Publication Publication Date Title
IL268417B2 (en) Methods for cell-type specific profiling to identify drug targets
JP2020508652A5 (https=)
US9952216B2 (en) Brain-specific enhancers for cell-based therapy
Liu et al. Multi-omic comparison of Alzheimer’s variants in human ESC–derived microglia reveals convergence at APOE
Ganis et al. Zebrafish globin switching occurs in two developmental stages and is controlled by the LCR
Ya et al. Application of spatial transcriptome technologies to neurological diseases
US20240000900A1 (en) Compositions and methods for treating diseases associated with an imprinting defect
Pozojevic et al. Single-Cell Sequencing in Neurodegenerative Disorders: J. Pozojevic, M. Spielmann
Dai et al. Regeneration leads to global tissue rejuvenation in aging sexual planarians
KR20210027575A (ko) Fam50a 유전자를 녹아웃시킨 동물모델 및 이의 용도
Lamanna et al. Reconstructing the ancestral vertebrate brain using a lamprey neural cell type atlas
Pereira et al. In and out: Benchmarking in vitro, in vivo, ex vivo, and xenografting approaches for an integrative brain disease modeling pipeline
Siniscalco et al. Barcoding Notch signaling in the developing brain
Arber et al. Microglia contribute to the production of the amyloidogenic ABri peptide in familial British dementia
Menon et al. PATZ1 Reinstates a Growth-Permissive Chromatin Landscape in Adult Corticospinal Neurons After Injury
Kawaguchi et al. Chromatin states at homeoprotein loci distinguish axolotl limb segments prior to regeneration
JP2021524016A (ja) タンパク質のハイスループット分析法及びその適用ライブラリー
WO2023184528A1 (zh) 标记物基因在检测多能干细胞残留中的应用、检测方法及试剂盒
Lovatt et al. The astrocyte transcriptome
Sziraki Developing EasySci, a High-Throughput and Low-Cost Single-Cell Genomic Technique, to Study Aging and Alzheimer's Disease in Human and Mouse Brain
Lei et al. Spatially resolved gene regulatory and disease vulnerability map of the adult Macaque cortex
Hardt et al. Gene expression analysis defines differences between region-specific GABAergic neurons
JPWO2005030961A1 (ja) 新規な神経幹細胞マーカー
KR102139784B1 (ko) Gad 유전자의 프로모터를 포함하는 가바성 신경세포의 검출용 조성물
Alhesain Exploring expression of neurodevelopmental susceptibility genes in the fetal human thalamus and other related structures